Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Tarlatamab-dlle - IMDELLTRA
Product / population
IMDELLTRA intravenous tarlatamab-dlle kit; selected pharmacokinetic renal information only, not a step-up dosing or toxicity-management protocol.
Renal method
Source prints eGFR in mL/min without a BSA denominator; indexed versus nonindexed meaning is not resolved here.
Source revision
Prescribing information revised 11/2025.
Retrieved
2026-09-08
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
IMDELLTRA: official pharmacokinetics do not repair the partial RX page
The official selected section supplies renal pharmacokinetics, not a stand-alone dosing algorithm for severe impairment or dialysis. The RX rendering remains incomplete.
What to reconcile: Do not convert unchanged pharmacokinetics into an unrestricted no-adjustment recommendation; clarify the source eGFR units.
DailyMed / Amgen Inc. · IMDELLTRA intravenous tarlatamab-dlle kit; selected pharmacokinetic renal information only, not a step-up dosing or toxicity-management protocol.
Renal method: Source prints eGFR in mL/min without a BSA denominator; indexed versus nonindexed meaning is not resolved here. Source date: Prescribing information revised 11/2025. Retrieved: 2026-09-08
Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
No clinically important pharmacokinetic difference was reported with mild or moderate impairment, described as eGFR 30 to <90 mL/min. Effects in severe impairment, eGFR 15 to <30, and end-stage disease, eGFR <15, are unknown. These are pharmacokinetic findings, not a stand-alone no-adjustment recommendation or dialysis schedule.
RDM44-official-tarlatamab-imdelltra-2f053beddf-C1 · Source locator: Section 12.3: Specific Populations, lines 924-925.
Source-specific limits
RX rendering remains incomplete and is not imported. Official label page update and PI revision are different dates.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.